Representative Matters: Represented Velicept Therapeutics Inc, a specialty pharmaceuticals company, in its successful completion of a $6.3 million Series B financing, which also added a third investor, an international life sciences focused venture capital fund.; Represented Complexa Inc., a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases, in connection with the sale of $62 million of Series C Preferred Stock to various investors, including lead investors New Enterprise Associates and Pfizer Venture Investments, LLC.; Represented VenatoRx Pharmaceuticals, Inc., a biopharmaceutical company developing next-generation antibiotics, in connection with the sale of $42 million of Series B Preferred Stock to various investors, including Abingworth, Foresite Capital and lead investor Versant Ventures.; Represented Iroko Pharmaceuticals, LLC in connection with a $140 million secured loan facility with CRG, a healthcare investment fund, and the simultaneous pay-off of Iroko's loan facility with another lender.; Represented a dermatological pharmaceutical company that is developing a drug, presently in Phase IIa, for the treatment of various cutaneous inflammatory disorders, in a $5 million venture loan.; Represented Unilife Corp. (NASDAQ: UNIS / ASX: UNS) in connection with its announced effort to seek strategic alternatives, culminating in a strategic collaboration with Amgen Inc. (NASDAQ: AMGN) for Unilife's wearable injectable drug delivery systems to use with Amgen's biologics and other medicines. The deal provides Unilife with investments of up to $90 million from Amgen and restructures Unilife's existing debt with OrbiMed.; Represented Clarion Capital Partners and its portfolio company, HR Outsourcing Holdings, Inc., a professional employer organization based in Atlanta, Georgia, in the acquisition of the outstanding capital stock of Fortune Financial, Inc., another professional employer organization based in Tampa, Florida, as well as the related financing transaction.; Represented Velicept Therapeutics, a specialty pharmaceutical company, in its acquisition of AltheRx, Inc. and $20 million Series B financing.; Represented a derm-focused pharmaceutical company in connection with the closings of two rounds of Series A-2 Preferred Stock to Third Point, New Science Ventures and Palo Alto, all venture capital firms active in the pharmaceutical space, for a cumulative total of $10 million.; Represented the owners of a construction management and consulting company, in the sale of all of the membership interests to a subsidiary of a NYSE listed global provider of architecture, design, engineering, and construction services.; Represented Vonage Holdings Corp. in its acquisition of gUnify, Inc., a cloud-based technology company whose middleware solution integrates the Company's cloud communications platform with widely used SaaS business applications, including Google for Work, Zendesk, Salesforce's Sales Cloud, Clio, and other CRM solutions.; Represented a pain-focused pharmaceutical company in closing a $30 million venture loan. The lender is an investment firm dedicated to the healthcare sector.; Represented Aclaris Therapeutics, Inc., a specialty pharmaceutical company with a focus on the development of novel topical dermatological therapies, in connection with the sale of $21.3 million of Series B Preferred Stock.; Represented Current Analysis, Inc., an IT and telecom market-research firm, in the sale of the company to Progressive Digital Media Group through a merger transaction for a purchase price of $19.6 million.; Represented BeachGlow: Concerts for Charity, Inc., a non-profit concert producer, in helping the organization incorporate, obtain tax exempt status and negotiate various contracts pertaining to a concert.; Represented Ludwig Bohler in the sale of his interests in Bohler Engineering, P.C. and a series of affiliated entities to employees who collectively owned most of the interests in the acquired entities not previously owned directly or indirectly by Mr. Bohler.; Represented Iroko Pharmaceuticals, a global specialty pharmaceutical company dedicated to advancing the science of responsible pain management, in securing $75 million in debt financing to support general business operations and the commercialization of Iroko's FDA-approved ZORVOLEX (diclofenac), a drug that uses iCeutica Inc.'s proprietary SoluMatrix Fine Particle Technology to both reduce the dosage of active ingredients ingested by the patient and accelerate the dissolution of the drug in the patient.; Represented Alexar Therapeutics, Inc., a newly formed derm-focused pharmaceutical company, in connection with the sale of $21.5 million of Series A-1 and Series A-2 Preferred Stock to Third Point, New Science Ventures and Palo Alto, venture capital firms active in the pharmaceutical space, and the simultaneous closing of the purchase of the stock of Anayaderm, a development-stage pharmaceutical company.; Represented a French media and sports management company in connection with the acquisition by its U.S. subsidiary of a golf events management company.